Endothelial biomarkers and platelet reactivity on ticagrelor versus clopidogrel in patients after acute coronary syndrome with and without concomitant type 2 diabetes: a preliminary observational study

Table 2 Platelet reactivity, sP-selectin and endothelial biomarkers in patients on DAPT with ticagrelor and clopidogrel stratified by diabetes status

Characteristic	Type 2 diabetes		No diabetes		p^a
Characteristic	Ticagrelor n = 30	Clopidogrel n = 31	Ticagrelor n = 32	Clopidogrel n = 33	p^a
Platelet aggregability	136 ± 69^**	254 ± 111	159 ± 83^**	260 ± 128	n.s
(AU * min)
sP-selectin (µg/L)	84 [72–106]^*	114 [83–142]	88 [75–110]^*	118 [81–145]	n.s.^b
Endothelial biomarkers
sVCAM-1 (µg/L)	758 ± 162^*	913 ± 217	872 ± 203	821 ± 210	< 0.05
sE-selectin (µg/L)	45 [30–76]	48 [32–71]	44 [31–74]	49 [30–77]	n.s.^b
MCP-1 (ng/L)	451 ± 187	430 ± 165	429 ± 160	449 ± 174	n.s
ADMA (µmol/L)	0.50 ± 0.09	0.49 ± 0.10	0.51 ± 0.10	0.52 ± 0.10	n.s
SDMA (µmol/L)	0.48 ± 0.11	0.49 ± 0.10	0.48 ± 0.10	0.51 ± 0.10	n.s

Data are shown as mean ± SD or median [interquartile range]
ADMA asymmetric dimethylarginine, AU arbitrary units, MCP-1 monocyte chemoattractant protein-1, SDMA symmetric dimethylarginine, sE-selectin soluble E-selectin, sP-selectin soluble P-selectin, sVCAM-1 soluble vascular cell adhesion molecule-1, other abbreviations as in Table 1
^aFor interaction between ticagrelor use and diabetes status by 2-way ANOVA
^bFor log-transformed data
^*p < 0.01 vs. diabetic patients on clopidogrel (retained significance after Bonferroni correction)
^**p < 0.001 vs. patients on clopidogrel

ISSN: 1475-2840